51ÊÓƵ

Media Advisory  Monday, November 21, 2022

51ÊÓƵ awards $12 million for antiviral therapeutic development

Image

Scanning electron micrograph of Ebola virus particles (purple) both budding and attached to the surface of infected VERO E6 cells (green).

NIAID

What

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, recently awarded more than $12 million to three institutions for the development of antiviral therapies to treat diseases caused by viruses with pandemic potential. NIAID may award approximately $61.5 million total over five years if all contract options are exercised. The new product development contracts are part of the , which aims to accelerate the discovery, development and manufacturing of antiviral medicines.

Antivirals are treatments that fight viral infections by acting directly against the virus. Other types of therapies, not the focus of this program, harness the body’s immune system to fight infection. The new contracts will support the development of promising antiviral candidates from late-stage preclinical studies through investigational new drug application-enabling activities and clinical testing.

Alongside the new product development contracts, NIAID already supports nine . The AViDD Centers conduct research on the early-stage identification and validation of novel viral targets and identification and early-stage characterization of antiviral drug candidates.

The new product development contracts include:

Optimization of Broad-Spectrum Filovirus Inhibitors that Target Viral Glycoprotein
Principal investigator: Terry Bowlin, Ph.D.
Institute: Microbiotix, Inc., Worcester, Massachusetts
Base funding amount: $2,069,416
NIAID contract: 75N93023C00001 

Development of a Novel 2-Pyrimidone (SRI-42718) as a Potent Inhibitor of Chikungunya Virus Infection and Disease
Principal investigator: Daniel Streblow, Ph.D.
Institute: Oregon Health and Science University, Portland
Base funding amount: $4,696,452
NIAID contract: 75N93023C00002

Development of an Orally Available Antiviral Drug for Yellow Fever
Principal investigator: Jinhong Chang, M.D., Ph.D.
Institute: Baruch S. Blumberg Institute, Doylestown, Pennsylvania
Base funding amount: $5,493,876
NIAID contract: 75N93023C00003

For more information about the APP, please visit: .

Who

Emily Erbelding, M.D., M.P.H., director of NIAID’s Division of Microbiology and Infectious Diseases, is available for comment.

Contact

To schedule interviews, please contact the NIAID News & Science Writing Branch, (301) 402-1663, niaidnews@niaid.nih.gov.

NIAID conducts and supports research—at 51ÊÓƵ, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the . 

About the National Institutes of Health (51ÊÓƵ): 51ÊÓƵ, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. 51ÊÓƵ is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about 51ÊÓƵ and its programs, visit www.nih.gov.

51ÊÓƵ…Turning Discovery Into Health^®